Basel, 03 October 2017 Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams The NAVIFY Tumor Board solution is a new, cloud-based software solution that fundamentally changes the way oncology care teams prepare for, conduct and document clinical treatment decisions for cancer patients It supports care team collaboration and standardizes... Read more
OXFORD, United Kingdom and MARLBOROUGH, Mass., September 27, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision of the U.S. District Court for the District of Massachusetts in the Company’s patent infringement... Read more
First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — September 27, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on September 26, 2017. This... Read more
FRANKLIN LAKES, N.J., Sept. 26, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test... Read more
Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SANTA CLARA, Calif., September 22, 2017 Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by U.S. Food and Drug... Read more
New Facility Helps Scientists Advance Translational Medical Research WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the opening of the Translational Medical Engineering Demonstration Laboratory at a ceremony on September 19. Co-founded with the State Key Laboratory of Biochemical Engineering, this facility will serve as a center for... Read more
Tokyo, Japan, September 21, 2017—Hitachi High-Technologies Corporation (TSE: 8036, Hitachi High-Tech) announced today that it would enter the diagnostic testing service business by accepting a private placement of new shares by MagArray, Inc. (MagArray) of the U.S. to make it an equity-method affiliate. Hitachi High-Tech has made the field of biotechnology and healthcare its priority.... Read more
Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications SANTA CLARA, Calif., September 19, 2017 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma (UC) and of squamous cell carcinoma... Read more
Basel, 15 September 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement Roche (SIX: RO, ROG; OTCQX: RHHBY): Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study... Read more
In-Depth Genomics Leverages PerkinElmer’s Comprehensive Sequencing Services to Provide Whole Genome Sequencing to Neurology Patients National Society of Genetic Counselors Annual Conference, Columbus, Ohio, Booth #535 –September 14, 2017 –PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced an innovative collaboration with In-Depth Genomics (IDG) to support IDG’s Whole Genome... Read more